Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

As Sandoz gears up to launch of one of the most anticipated biosimilars of the year, the company could face near-term ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

For the current quarter, Amgen is expected to post earnings of $5.01 per share, indicating a change of +6.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -3.6% over the last 30 ...